Cited by 225Colorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsColorectal Cancer Surgical Treatments

The DOI matches its Crossref record; 90 of the 91 references it cites were found in a registry or an index.

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

Open access

Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P.P., Normanno, N., Rachiglio, A.M., Maiello, E., Latiano, T., De Vita, F., Ciardiello, F.·2020·Annals of Oncology

DOI 10.1016/j.annonc.2019.10.007

Open this paper in CoChat — free account Open PDF

Abstract

Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorectal cancer (mCRC). Anti-EGFR monoclonal antibodies (MoAbs), such as cetuximab or panitumumab, in combination with chemotherapy are effective treatment options for patients with RAS and BRAF wild-type mCRC. Nevertheless, several issues are still open concerning the optimal use of anti-EGFR drugs in the continuum of care of mCRC. Novel approaches for increasing the efficacy of anti-EGFR therapies include better molecular selection of EGFR-dependent mCRC, intensification of chemotherapy, combination of anti-EGFR MoAbs and immune checkpoint inhibitors, and reintroduction of EGFR blockade or 'rechallenge' in selected patients who have previously responded to anti-EGFR MoAb therapy. An extensive translational research program was conducted in the Cetuximab After Progression in KRAS wIld-type colorectal cancer patients-Gruppo Oncologico dell' Italia Meridionale (CAPRI-GOIM) study with the aims of determining which subgroups of patients could benefit from the continuous inhibition of EGFR, from evaluating the role of liquid biopsy-based and its concordance with tissue-based molecular testing, and from investigating novel potential mechanisms of resistance to anti-EGFR therapies. In this review, we summarize the translational and clinical findings of the CAPRI-GOIM program in the context of the current knowledge of therapeutic strategies and of ongoing research on more appropriate uses of anti-EGFR therapies in RAS and BRAF wild-type mCRC patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2019.10.007

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citation
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citation
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
Self-citation
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citation
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2806 · Cited by 1,216
Continuation of Bevacizumab after First Progression in Metastatic Colorectal Cancer (ML18147): A Randomised Phase 3 Trial
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,088
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Self-citation
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.
Piedbois, P., Rougier, P. R., Buyse, M. E., Pignon, J., RYAN, L. M., Hansen, R., Zee, B. C.-Y., Weinerman, B., Pater, J., Leichman, C. G., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.301 · Cited by 979
Ramucirumab versus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Progressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Randomised, Double-Blind, Multicentre, Phase 3 Study
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
International Trends in Colorectal Cancer Incidence Rates
Jemal, A., & Ward, E. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0090 · Cited by 837
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citation
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775
TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer
Linger, R. M. A., Keating, A. K., Earp, H. S., & Graham, D. K. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00002-x · Cited by 750
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
Cunningham, D., Láng, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D. J., Osborne, S., Andre, N., Waterkamp, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70154-2 · Cited by 656
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654 · cited 1×
“Intratumor genetic heterogeneity refers to the concept that in a single tumor, different cancer cell clones, carrying different molecular alterations, coexist.(30) Recently, greater attention has been focused on the issue of tumor heterogeneity, since the presence of cancer cell clones with different mutations could c…”
Background
Final Results from PRIME: Randomized Phase III Study of Panitumumab with FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Bokemeyer, C., Cutsem, E. V., Rougier, P. R., Ciardiello, F., Heeger, S., Schlichting, M., Celik, I., & Köhne, C. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.057 · Cited by 581
Self-citation
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573
Self-citation
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Baldus, S. E., Schaefer, K.-L., Engers, R., Hartleb, D., Stoecklein, N. H., & Gabbert, H. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2446 · Cited by 432
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial
Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347
Self-citation
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
Vidal, J., Muinelo, L., Dalmases, A., Jones, F. S., Edelstein, D. L., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx125 · Cited by 345
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 310
Self-citation
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
Parseghian, C. M., Loree, J. M., Morris, V. K., Liu, X., Clifton, K., Napolitano, S., Henry, J. T., Pereira, A. A. L., Vilar, E., Johnson, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy509 · Cited by 258
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
Morelli, M. P., Overman, M. J., Dasari, A. N., Kazmi, S. M. A., Mazard, T., Vilar, E., Morris, V. K., Lee, M. S., Herron, D. S., Eng, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv005 · Cited by 256
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
Siena, S., Bianchi, A. S., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F. M., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 254
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
Khan, K. H., Cunningham, D., Werner, B., Vlachogiannis, G., Spiteri, I., Heide, T., Fernández-Mateos, J., Vatsiou, A. I., Lampis, A., Darvish-Damavandi, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0891 · Cited by 227
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R. N., Christie, M., Drummond, K. J., Thomson, B. N. J., Usatoff, V., Evans, P. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1720 · Cited by 217
Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma
Marks, J. L., Gong, Y., Chitale, D. A., Golas, B., McLellan, M. D., Kasai, Y., Ding, L., Mardis, E. R., Wilson, R. K., Solit, D. B., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0099 · Cited by 213
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G., Scartozzi, M., Mancuso, A. P., Frezza, A. M., Venditti, O., Imperatori, M., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr623 · Cited by 212
Self-citation
AXL Mediates Resistance to Cetuximab Therapy
Brand, T. M., Iida, M., Stein, A. P., Corrigan, K. L., Braverman, C. M., Luthar, N., Toulany, M., Gill, P. S., Salgia, R., Kimple, R. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0294 · Cited by 198
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Ferris, R. L., Lenz, H., Trotta, A. M., García‐Foncillas, J., Schulten, J., Audhuy, F., Merlano, M. C., & Milano, G. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.008 · Cited by 193
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
Grasselli, J., Élez, E., Caratù, G., Matito, J., Santos, C., Macarulla, T. M., Vidal, J., García, M. D. S., Viéitez, J. M., Páez, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx112 · Cited by 188
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Bianchi, A. S., Amatu, A., Porcu, L., Ghezzi, S., Lonardi, S., Leone, F., Bergamo, F., Fenocchio, E., Martinelli, E., Borelli, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0785 · Cited by 174
Self-citation
Clinical Relevance of KRAS -Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
Laurent‐Puig, P., Pekin, D., Normand, C., Kotsopoulos, S. K., Nizard, P., Perez‐Toralla, K., Rowell, R. K., Olson, J., Srinivasan, P., Corre, D. L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0983 · Cited by 166
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
Dechant, M., Weisner, W., Berger, S., Peipp, M., Beyer, T. D., Schneider‐Merck, T., van Bueren, J. J. L., Bleeker, W. K., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6226 · Cited by 165
The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios
Normanno, N., Cervantes, A. M. R., Ciardiello, F., Luca, A. D., & Pinto, C. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.007 · Cited by 152
Self-citation
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
Normanno, N., Rachiglio, A. M., Lambiase, M., Martinelli, E., Fenizia, F., Esposito, C., Roma, C., Troiani, T., Rizzi, D., Tatangelo, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv176 · Cited by 150
Self-citation
Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
Troiani, T., Martinelli, E., Napolitano, S., Vitagliano, D., Ciuffreda, L. P., Costantino, S., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0423 · Cited by 150
Self-citation
MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation
Rho, J. K., Choi, Y. J., Kim, S. Y., Kim, T. W., Choi, E. K., Yoon, S.-J., Park, B. M., Park, E., Bae, J. H., Choi, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1103 · Cited by 144
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Dunne, P. D., Dasgupta, S., Blayney, J. K., McArt, D. G., Redmond, K. L., Weir, J.-A., Bradley, C. A., Sasazuki, T., Shirasawa, S., Wang, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0603 · Cited by 140
Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer
Hench, I. B., Hench, J., & Tolnay, M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00009 · Cited by 126
Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 124
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Self-citation
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu230 · Cited by 116
Self-citation
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer
Cremolini, C., Antoniotti, C., Lonardi, S., Aprile, G., Bergamo, F., Masi, G., Grande, R., Tonini, G., Mescoli, C., Cardellino, G. G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5314 · Cited by 116
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
Normanno, N., Abate, R. E., Lambiase, M., Forgione, L., Cardone, C., Iannaccone, A., Sacco, A., Rachiglio, A. M., Martinelli, E., Rizzi, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx417 · Cited by 115
Self-citation
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer
Pietrantonio, F., Morano, F., Corallo, S., Miceli, R., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Bergamo, F., Bianchi, A. S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1467 · Cited by 114
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
Self-citation
EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients
Srivatsa, S., Paul, M. C., Cardone, C., Holcmann, M., Amberg, N., Pathria, P., Diamanti, M. A., Linder, M., Timelthaler, G., Dienes, H. P., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.053 · Cited by 98
Self-citation
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
Ciardiello, F., Normanno, N., Martinelli, E., Troiani, T., Pisconti, S., Cardone, C., Nappi, A., Bordonaro, R., Rachiglio, A. M., Lambiase, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw136 · Cited by 94
Self-citation
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
Martini, G., Cardone, C., Vitiello, P. P., Belli, V., Napolitano, S., Troiani, T., Ciardiello, D., Corte, C. M. D., Morgillo, F., Matrone, N., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0539 · Cited by 90
Self-citation
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies
Mauri, G., Pizzutilo, E. G., Amatu, A., Bencardino, K. B., Palmeri, L., Bonazzina, E. F., Tosi, F., Stella, G. C., Burrafato, G., Scaglione, F., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.006 · Cited by 89
Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer
De Robertis, M., Loiacono, L., Fusilli, C., Poeta, M. L., Mazza, T., Sanchez, M., Marchionni, L., Signori, E., Lamorte, G., Vescovi, A. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0709 · Cited by 78
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma
Korphaisarn, K., Morris, V. K., Overman, M. J., Fogelman, D. R., Kee, B. K., Raghav, K. P. S., Manuel, S., Shureiqi, I., Wolff, R. A., Eng, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16848 · Cited by 67
AXL is an oncotarget in human colorectal cancer
Martinelli, E., Martini, G., Cardone, C., Troiani, T., Liguori, G., Vitagliano, D., Napolitano, S., Morgillo, F., Rinaldi, B., Melillo, R. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3962 · Cited by 66
Self-citation
Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients
Lupini, L., Bassi, C., Mlčochová, J., Musa, G., Russo, M., Vychytilova‐Faltejskova, P., Svoboda, M., Sabbioni, S., Němeček, R., Slabý, O., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1752-5 · Cited by 58
RAS Signaling in Colorectal Carcinomas through Alteration of RAS, RAF, NF1, and/or RASSF1A
Ahlquist, T. C., Bottillo, I., Danielsen, S. A., Meling, G. I., Rognum, T. O., Lind, G. E., Dallapiccola, B., & Lothe, R. A. (2008) · Neoplasia · doi:10.1593/neo.08312 · Cited by 57
The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies
Esposito, C., Rachiglio, A. M., La Porta, M. L., Sacco, A., Roma, C., Iannaccone, A., Tatangelo, F., Forgione, L., Pasquale, R., Barbaro, A., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26340 · Cited by 53
Self-citation
Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents
Rachiglio, A. M., Lambiase, M., Fenizia, F., Roma, C., Cardone, C., Iannaccone, A., Luca, A. D., Carotenuto, M., Frezzetti, D., Martinelli, E., et al. (2019) · Cancers · doi:10.3390/cancers11060859 · Cited by 43
Self-citation
Inhibitory role of Gas6 in intestinal tumorigenesis
Akitake, R., Seno, H., Nakatsuji, M., Kimura, Y., Nakanishi, Y., Yoshioka, T., Kanda, K., Kawada, M., Kawada, K., Sakai, Y., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt069 · Cited by 42
Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients
Botta, C., Bestoso, E., Apollinari, S., Cusi, M. G., Pastina, P., Abbruzzese, A., Sperlongano, P., Misso, G., Caraglia, M., Tassone, P., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31825943aa · Cited by 35
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
Martinelli, E., Troiani, T., Sforza, V., Martini, G., Cardone, C., Vitiello, P. P., Ciardiello, D., Rachiglio, A. M., Normanno, N., Bianchi, A. S., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000299 · Cited by 34
Self-citation
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy
Vidal, J., Bellosillo, B., Vivas, C. S., Alfonso, P. G., Carrato, A., Cano, M. T., García‐Carbonero, R., Élez, E., Losa, F., Massutí, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz005 · Cited by 28
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
Borelli, B., Moretto, R., Lonardi, S., Bonetti, A. V., Antoniotti, C., Pietrantonio, F., Masi, G., Burgio, V., Marmorino, F., Salvatore, L., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000403 · Cited by 25
Self-citation
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
Stein, A., Binder, M., Al‐Batran, S., Hinke, A., Waberer, L., Goekkurt, E., Meyer, T., Statovci, D., Depenbusch, R., Riera‐Knorrenschild, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3561 · Cited by 24
A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer
Rosati, G., Aprile, G., Cardellino, G. G., & Avallone, A. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.01.006 · Cited by 21
Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study
Feng, Q., Wei, Y., Ren, L., Zheng, P., Yu, Y., Ye, Q., Ding, J., Chen, J., Chang, W., Zhong, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7193 · Cited by 17
The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences
Normanno, N., Pinto, C., Castiglione, F., Fenizia, F., Barberis, M. C. P., Marchetti, A., Fontanini, G., Rosa, G. D., & Taddei, G. L. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0655-1 · Cited by 14
Self-citation
Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis
Leśniewski-Kmak, K., Моисеенко, В., Saunders, M. P., Wasan, H. S., Argilés, G., Borg, C., Creemers, G., Fedyanin, M., Glynne‐Jones, R., Pfeiffer, P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy149.021 · Cited by 14
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
Martinelli, E., Cardone, C., Troiani, T., Normanno, N., Pisconti, S., Sforza, V., Bordonaro, R., Rachiglio, A. M., Lambiase, M., Latiano, T., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000086 · Cited by 11
Self-citation
Outcome of patients with KRAS exon 2 wildtype (KRAS-wt) metastatic colorectal carcinoma (mCRC) with cetuximab-based first-line treatment in the noninterventional study ERBITAG and impact of comorbidity and age.
Sahm, S. W., Goehler, T., Hering-Schubert, C., Janßen, J., Neumann, U. P., Schwittay, M., Zahn, M., Stenzel, K. G., Steinbach-Buechert, A. K., & Overkamp, F. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.651 · Cited by 8
Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials
Matos, I. G., Noguerido, A., Ros, J., Mulet-Margalef, N., Argilés, G., Élez, E., & Tabernero, J. M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1599860 · Cited by 8
Abstract 36: The OncoNetwork Consortium: A European Collaborative Research study on the development of an Ion AmpliSeq gene panel targeting hot spots in colon and lung cancers.
Normanno, N., Petraroli, R. P., Rico, A., Kurth, H. M., Tops, B. B. J., Amato, E., Mafficini, A., Corre, D. L., Rachiglio, A. M., Reiman, A., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-36 · Cited by 7
Self-citation
Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).
Geißler, M., Riera‐Knorrenschild, J., Martens, U. M., Held, S., Greeve, J. C., Florschütz, A., Ettrich, T. J., Kanzler, S., Tannapfel, A., Heinemann, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3511 · Cited by 7
AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Cardone, C., Blauensteiner, B., Moreno‐Viedma, V., Paul, M. C., Martini, G., Vitiello, P. P., Ciardiello, D., Borrelli, C., Poliero, L., Vitale, P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy269.094 · Cited by 4
Self-citation

Sorted by citations

Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910260 · Cited by 402
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
Timar, J., & Kashofer, K. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09915-5 · Cited by 334
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Precision oncology in metastatic colorectal cancer — from biology to medicine
Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 240
Self-citation
Exosomal targeting and its potential clinical application
He, J., Ren, W., Wang, W., Han, W., Jiang, L., Zhang, D., & Guo, M. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01087-1 · Cited by 210

See all 225

Authors: Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., De Vita, F., & Ciardiello, F.
Affiliations: University of Campania "Luigi Vanvitelli" (IT)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Casa Sollievo della Sofferenza (IT)
Corresponding author: Ciardiello, F.
ORCID: Ciardiello, D.
Martini, G.
Troiani, T.
Cardone, C.
Vitiello, P.P.
Normanno, N.
Rachiglio, A.M.
Maiello, E.
Ciardiello, F.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2020-01
Volume: 31
Issue: 1
Pages: 30-40
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1016/j.annonc.2019.10.007
OpenAlex: W2999771324
Cited by: 225
References: 91
Citations by year: 2026: 11 · 2025: 25 · 2024: 32 · 2023: 42 · 2022: 66 · 2021: 32 · 2020: 16
FWCI: 4.19
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 85 d)
Locations: Annals of Oncology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
Funders: Associazione Italiana per la Ricerca sul Cancro
Regione Campania
Sanofi
Amgen
Merck KgA
Roche
Servier
Bayer
Array
MSD
BMS
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords: EGFR inhibitors, metastatic colorectal cancer, cetuximab, panitumumab, RAS wild-type, BRAF wild-type, drug rechallenge, immune checkpoint inhibitors, liquid biopsy, resistance mechanisms, molecular selection, chemotherapy intensification
MeSH terms: Cetuximab, Panitumumab, Antineoplastic Agents, Humans, Mutation, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks